KR102821650B1 - 신경변성 질환 치료제 - Google Patents
신경변성 질환 치료제 Download PDFInfo
- Publication number
- KR102821650B1 KR102821650B1 KR1020217012902A KR20217012902A KR102821650B1 KR 102821650 B1 KR102821650 B1 KR 102821650B1 KR 1020217012902 A KR1020217012902 A KR 1020217012902A KR 20217012902 A KR20217012902 A KR 20217012902A KR 102821650 B1 KR102821650 B1 KR 102821650B1
- Authority
- KR
- South Korea
- Prior art keywords
- aim
- disease
- brain
- gly
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Psychology (AREA)
- General Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018186759 | 2018-10-01 | ||
| JPJP-P-2018-186759 | 2018-10-01 | ||
| PCT/JP2019/038530 WO2020071318A1 (ja) | 2018-10-01 | 2019-09-30 | 神経変性疾患治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210068104A KR20210068104A (ko) | 2021-06-08 |
| KR102821650B1 true KR102821650B1 (ko) | 2025-06-16 |
Family
ID=70054569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217012902A Active KR102821650B1 (ko) | 2018-10-01 | 2019-09-30 | 신경변성 질환 치료제 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12268729B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3862012A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7289033B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102821650B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112752583A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3114869C (cg-RX-API-DMAC7.html) |
| IL (1) | IL281869B2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202103250UA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020071318A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111315880B (zh) | 2017-11-16 | 2023-10-31 | 宫崎彻 | 突变型aim |
| US20230358975A1 (en) | 2020-07-10 | 2023-11-09 | Niharika Kohli | Integrated optical microelectronic mechanical systems devices and methods |
| JP7849078B2 (ja) * | 2022-01-29 | 2026-04-21 | シャンハイ、レイジング、ファーマシューティカル、カンパニー、リミテッド | Tpkを発現する組換えウイルスおよびアルツハイマー病の処置におけるその使用 |
| WO2023149411A1 (ja) | 2022-02-01 | 2023-08-10 | いなば食品株式会社 | 動物用の医薬又は食品組成物 |
| JP2025128418A (ja) * | 2022-07-12 | 2025-09-03 | 徹 宮崎 | 腎臓結石の治療または予防剤 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004500101A (ja) | 2000-03-08 | 2004-01-08 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 免疫系関連ポリヌクレオチド、ポリペプチド、および抗体 |
| US20150094268A1 (en) | 2012-04-27 | 2015-04-02 | Toru Miyazaki | Prophylactic or therapeutic agent for hepatic diseases |
| US20180078539A1 (en) * | 2016-03-23 | 2018-03-22 | Louis Habash | T-cell regulation in t-cell mediated diseases by reducing pathogenic function of th17 in a human subject through treatment with a nitroxide |
| KR101870246B1 (ko) | 2014-02-07 | 2018-06-22 | 토루 미야자키 | 신질환의 예방 또는 치료제 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6324392A (ja) | 1986-07-15 | 1988-02-01 | 田中 浩 | カ−テン等設置用防犯装置 |
| WO2000024392A1 (en) | 1998-10-26 | 2000-05-04 | Sumitomo Pharmaceuticals Company, Limited | β-AMYLOID FORMATION INHIBITORS |
| EP1668143B1 (en) | 2003-09-30 | 2013-03-20 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| PL2246427T3 (pl) | 2008-02-08 | 2017-06-30 | Immunas Pharma, Inc. | Przeciwciała zdolne do wiązania się swoiście do oligomerów amyloidu beta i ich stosowanie |
| JP2010140531A (ja) | 2008-12-10 | 2010-06-24 | Elpida Memory Inc | 多i/oの半導体メモリの試験方法 |
| US20100331244A1 (en) | 2009-06-01 | 2010-12-30 | The University Of Tokyo | Pharmaceutical composition, food or drink, and methods related thereto |
| EP2463369A4 (en) | 2009-08-07 | 2013-09-18 | Kyowa Hakko Kirin Co Ltd | HUMANIZED ANTIBODIES AGAINST AMYLOID B OLIGOMERS |
| JPWO2011145725A1 (ja) | 2010-05-20 | 2013-07-22 | 宮崎 徹 | Aim関連疾患の診断方法及び診断用キット |
| US10738326B2 (en) | 2010-10-27 | 2020-08-11 | Jichi Medical University | Adeno-associated virus vector for gene transfer to nervous system cells |
| JP2013162021A (ja) | 2012-02-07 | 2013-08-19 | Seiko Epson Corp | 波長変換素子、光源装置、及びプロジェクター |
| JP2015119253A (ja) | 2013-12-17 | 2015-06-25 | 船井電機株式会社 | デジタルテレビ放送録画装置およびデジタルテレビ放送録画方法 |
| JP6083549B1 (ja) | 2016-06-03 | 2017-02-22 | 株式会社制御システム研究所 | 特定パケット中継機能付きデータダイオード装置 |
| WO2018189661A2 (en) * | 2017-04-10 | 2018-10-18 | Palti Yoram Prof | Methods and compounds for treating diabetes |
| JP6189566B1 (ja) | 2017-05-08 | 2017-08-30 | 月桂冠株式会社 | 有機酸生成酒酵母株の製造方法、清酒の製造方法、および変異pex22遺伝子 |
-
2019
- 2019-09-30 JP JP2020550422A patent/JP7289033B2/ja active Active
- 2019-09-30 CN CN201980065100.3A patent/CN112752583A/zh active Pending
- 2019-09-30 SG SG11202103250UA patent/SG11202103250UA/en unknown
- 2019-09-30 EP EP19869231.1A patent/EP3862012A4/en active Pending
- 2019-09-30 CA CA3114869A patent/CA3114869C/en active Active
- 2019-09-30 KR KR1020217012902A patent/KR102821650B1/ko active Active
- 2019-09-30 WO PCT/JP2019/038530 patent/WO2020071318A1/ja not_active Ceased
- 2019-09-30 US US17/280,157 patent/US12268729B2/en active Active
- 2019-09-30 IL IL281869A patent/IL281869B2/en unknown
-
2025
- 2025-03-11 US US19/076,595 patent/US20250213651A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004500101A (ja) | 2000-03-08 | 2004-01-08 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 免疫系関連ポリヌクレオチド、ポリペプチド、および抗体 |
| US20150094268A1 (en) | 2012-04-27 | 2015-04-02 | Toru Miyazaki | Prophylactic or therapeutic agent for hepatic diseases |
| KR101870246B1 (ko) | 2014-02-07 | 2018-06-22 | 토루 미야자키 | 신질환의 예방 또는 치료제 |
| US20180078539A1 (en) * | 2016-03-23 | 2018-03-22 | Louis Habash | T-cell regulation in t-cell mediated diseases by reducing pathogenic function of th17 in a human subject through treatment with a nitroxide |
Non-Patent Citations (1)
| Title |
|---|
| PNAS. 2011. Vol.108, No.29, pp.12072-12077. |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210068104A (ko) | 2021-06-08 |
| IL281869A (en) | 2021-05-31 |
| US12268729B2 (en) | 2025-04-08 |
| EP3862012A4 (en) | 2022-08-17 |
| EP3862012A1 (en) | 2021-08-11 |
| US20220000975A1 (en) | 2022-01-06 |
| WO2020071318A1 (ja) | 2020-04-09 |
| IL281869B1 (en) | 2026-02-01 |
| US20250213651A1 (en) | 2025-07-03 |
| JPWO2020071318A1 (ja) | 2021-09-02 |
| CA3114869A1 (en) | 2020-04-09 |
| CA3114869C (en) | 2023-10-03 |
| JP7289033B2 (ja) | 2023-06-09 |
| IL281869B2 (en) | 2026-06-01 |
| CN112752583A (zh) | 2021-05-04 |
| SG11202103250UA (en) | 2021-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250213651A1 (en) | Therapeutic agent for neurodegenerative disease | |
| JP6143015B2 (ja) | 肝疾患の予防または治療剤 | |
| US12435109B2 (en) | Compositions and methods for dissolving protein aggregates | |
| US12371462B2 (en) | Brown fat-selective adipokines | |
| WO2024014463A1 (ja) | 腎臓結石の治療または予防剤 | |
| HK40044839A (en) | Therapeutic agent for neurodegenerative disease | |
| HK40052931A (en) | Therapeutic agent for neurodegenerative disease | |
| US20220220178A1 (en) | Compositions for Treatment of Vascular Disease | |
| EP4378472A1 (en) | Therapeutic agent for ischemic disease | |
| JP7504490B2 (ja) | 重度腎不全に罹患するネコ科動物における尿毒症の悪化を抑制するための剤 | |
| WO2025249541A1 (ja) | 酸化ストレス抑制剤 | |
| US20260109741A1 (en) | Sting-targeting gene therapy | |
| CN118900844A (zh) | 用于溶解蛋白质聚集体的肽和其方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PX0901 | Re-examination |
St.27 status event code: A-2-3-E10-E12-rex-PX0901 |
|
| PX0701 | Decision of registration after re-examination |
St.27 status event code: A-3-4-F10-F13-rex-PX0701 |
|
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |